Staudigl Christine, Concin Nicole, Grimm Christoph, Pfeiler Georg, Nehoda Regina, Singer Christian F, Polterauer Stephan
Department of General Gynecology and Gynecologic Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.
PLoS One. 2015 Apr 27;10(4):e0125317. doi: 10.1371/journal.pone.0125317. eCollection 2015.
Gamma-glutamyltransferase (GGT) is a known marker for apoptotic balance and cell detoxification. Recently, an association of baseline GGT levels and breast cancer incidence, tumor progression and chemotherapy resistance was shown. The purpose of this study was to evaluate the association of pre-therapeutic GGT levels, clinical-pathological parameters and survival in patients with primary metastatic breast cancer (PMBC).
In this multicenter analysis, pre-therapeutic GGT levels and clinical-pathological parameters of 114 patients diagnosed with PMBC between 1996 and 2012 were evaluated. The association between GGT levels and clinical-pathological parameters were analysed. Patients were stratified into four GGT risk-groups (GGT < 18.00 U/L: normal low, 18.00 to 35.99 U/L: normal high, 36.00 to 71.99 U/L: elevated and ≥ 72.00 U/L: highly elevated) and survival analyses were performed.
Patients in the high risk GGT group had a poorer overall survival, when compared to the low risk group with five-year overall survival rates of 39.5% and 53.7% (p = 0.04), respectively. Patients with larger breast tumors had a trend towards higher GGT levels (p = 0.053). Pre-therapeutic GGT levels were not associated with indicators of aggressive tumor biology such as HER2-status, triple negative histology, or poorly differentiated cancers.
Pre-therapeutic GGT serum level might serve as a novel prognostic factor for overall-survival in patients with PMBC.
γ-谷氨酰转移酶（GGT）是一种已知的凋亡平衡和细胞解毒标志物。最近，研究表明基线GGT水平与乳腺癌发病率、肿瘤进展及化疗耐药性之间存在关联。本研究旨在评估原发性转移性乳腺癌（PMBC）患者治疗前GGT水平、临床病理参数与生存率之间的关联。
在这项多中心分析中，评估了1996年至2012年间确诊为PMBC的114例患者的治疗前GGT水平和临床病理参数。分析了GGT水平与临床病理参数之间的关联。患者被分为四个GGT风险组（GGT<18.00 U/L：正常低水平，18.00至35.99 U/L：正常高水平，36.00至71.99 U/L：升高，≥72.00 U/L：高度升高），并进行了生存分析。
与低风险组相比，高风险GGT组患者的总生存期较差，五年总生存率分别为39.5%和53.7%（p=0.04）。乳腺肿瘤较大的患者GGT水平有升高趋势（p=0.053）。治疗前GGT水平与HER2状态、三阴性组织学或低分化癌等侵袭性肿瘤生物学指标无关。
治疗前GGT血清水平可能作为PMBC患者总生存期的一个新的预后因素。
